Wellington Management Group LLP Sells 726,201 Shares of Zoetis Inc. $ZTS

Wellington Management Group LLP lowered its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 7.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,423,895 shares of the company’s stock after selling 726,201 shares during the period. Wellington Management Group LLP’s holdings in Zoetis were worth $677,201,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in shares of Zoetis by 10.8% during the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after buying an additional 3,845,869 shares during the period. J. Stern & Co. LLP lifted its position in shares of Zoetis by 12,431.2% during the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after acquiring an additional 23,877,416 shares during the period. State Street Corp lifted its position in shares of Zoetis by 0.8% during the 4th quarter. State Street Corp now owns 19,796,891 shares of the company’s stock valued at $2,490,845,000 after acquiring an additional 149,382 shares during the period. Geode Capital Management LLC boosted its stake in Zoetis by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock worth $1,420,294,000 after acquiring an additional 189,235 shares in the last quarter. Finally, Deutsche Bank AG boosted its stake in Zoetis by 5.8% during the second quarter. Deutsche Bank AG now owns 5,851,737 shares of the company’s stock worth $420,506,000 after acquiring an additional 319,709 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Price Performance

Shares of NYSE ZTS opened at $77.45 on Friday. Zoetis Inc. has a fifty-two week low of $71.00 and a fifty-two week high of $156.49. The stock has a market cap of $32.00 billion, a price-to-earnings ratio of 12.76, a PEG ratio of 1.80 and a beta of 0.74. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. The firm’s 50-day simple moving average is $75.57 and its 200 day simple moving average is $95.62.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company’s revenue for the quarter was down .2% on a year-over-year basis. During the same period in the previous year, the company posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, research analysts anticipate that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Morgan Stanley set a $85.00 price target on shares of Zoetis in a research note on Friday, August 7th. Cantor Fitzgerald set a $94.00 price objective on shares of Zoetis in a research report on Tuesday. Weiss Ratings downgraded Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. Stifel Nicolaus cut their price target on Zoetis from $85.00 to $80.00 and set a “hold” rating on the stock in a report on Thursday, August 20th. Finally, Piper Sandler cut their price target on Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a report on Monday, August 10th. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Zoetis currently has a consensus rating of “Hold” and an average target price of $107.43.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.